Top Industry Leaders in the Purpura treatment Market
Latest Purpura Treatment Companies Updates:
Dec 2023
Amgen Launched their Romiplostim (Nplate®) for the treatment of chronic ITP in previously-treated adult patients, offering a new option for this challenging condition.Collaborated with research institutions to investigate the potential of Romiplostim in various purpura types and personalized treatment strategies.
Grifols Biological Received FDA approval for their WinRho® SDF (solvent detergent-treated) product for the prevention of Rhesus alloimmunization, a potential contributor to ITP in newborns.Focused on providing safe and effective plasma-derived therapeutics for various blood disorders, including purpura-related complications.
AstraZeneca Received positive Phase III data on their Caplacizumab (Ultomiris®) for the prevention of TTP recurrences in adult patients, offering potential for long-term disease control.Partnered with patient advocacy groups to raise awareness about TTP and improve access to specialized care.
Sanofi S.A. Collaborated with a biotech company to develop a novel anti-CD41 monoclonal antibody for the treatment of ITP, aiming to provide a new therapeutic option with different mechanisms of action.Focused on expanding their portfolio of blood disorder treatments through partnerships and internal research and development efforts.
Roche Holding AG Introduced their Antero® point-of-care hemostasis analyzer for rapid and on-site platelet count testing, facilitating faster diagnosis and management of purpura conditions.Emphasized their commitment to developing innovative diagnostic tools for improved efficiency and patient care in blood disorders.
List of Purpura Treatment Key companies in the market
- Novartis AG
- Amgen Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc.
- Sanofi Winthrop Industrie S.A.